{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:13:58Z","timestamp":1791656038116,"version":"4.3.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004466","name":"Centre International de Recherches M\u00e9dicales de Franceville","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004466","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012947","name":"Institut de Recherche pour le D\u00e9veloppement","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The projected UNAIDS goal of ending AIDS by 2030 requires significant global efforts to improve current and future ART strategies. In this study, we assessed viral load (VL) suppression and acquired drug resistance, as well as future efficacy of dolutegravir-based combinations for patients living in semi-rural regions of Gabon.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible study participants were adults receiving ART and recruited between 2018 and 2019 in Franceville, Gabon. VL testing was conducted to assess VL suppression and HIV drug resistance (HIVDR) testing was performed to identify resistance mutations and assess their impact on ongoing and future ART regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We recruited 219 participants overall. The median time on ART was 27\u2009months and 216\/219 participants were on first-line ART. VL suppression (VL\u200a&amp;lt;\u200a1000\u2009copies\/mL) was 57.1% (95% CI 50.5\u201363.8) overall; 59.4% (51.4\u201367.5) and 52.2% (40.3\u201364.2) for women and men, respectively. The overall prevalence of HIVDR was 21.9% among the study population and 67.2% among those who failed ART. Presence of both NRTI and NNRTI mutations was found in 84.6% of sequences with drug resistance mutations, and full activity of a dolutegravir-based first-line regimen including tenofovir disoproxil fumarate\/lamivudine\/dolutegravir was expected only for 5\/39 patients with a resistant virus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study shows a very low rate of VL suppression in a semi-rural context in Africa. Moreover, the high burden of HIVDR has affected both current and newly recommended ART strategies. Better management of ART in resource-limited settings is still a challenging ambition.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa537","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T23:53:21Z","timestamp":1607558001000},"page":"1051-1056","source":"Crossref","is-referenced-by-count":12,"title":["High rate of virological failure and HIV drug resistance in semi-rural Gabon and implications for dolutegravir-based regimen efficacy"],"prefix":"10.1093","volume":"76","author":[{"given":"J\u00e9ordy D","family":"Engone-Ondo","sequence":"first","affiliation":[{"name":"Unit\u00e9 des Infections R\u00e9trovirales et Pathologies Associ\u00e9es, Centre International de Recherches M\u00e9dicales de Franceville (CIRMF), BP 769 Franceville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Mouinga-Ond\u00e9m\u00e9","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Infections R\u00e9trovirales et Pathologies Associ\u00e9es, Centre International de Recherches M\u00e9dicales de Franceville (CIRMF), BP 769 Franceville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia E","family":"L\u00e9kana-Douki","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des \u00c9mergences Virales, Centre International de Recherches M\u00e9dicales de Franceville (CIRMF), BP 769 Franceville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye","family":"Dian\u00e9","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Infections R\u00e9trovirales et Pathologies Associ\u00e9es, Centre International de Recherches M\u00e9dicales de Franceville (CIRMF), BP 769 Franceville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony I","family":"Mamimandjiami","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Infections R\u00e9trovirales et Pathologies Associ\u00e9es, Centre International de Recherches M\u00e9dicales de Franceville (CIRMF), BP 769 Franceville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavie","family":"Banga","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des \u00c9mergences Virales, Centre International de Recherches M\u00e9dicales de Franceville (CIRMF), BP 769 Franceville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy-Roger","family":"Ndong-Atome","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biochimie, Facult\u00e9 des Sciences, Universit\u00e9 des Sciences et Techniques de Masuku (USTM), BP 901 Franceville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avelin F","family":"Aghokeng","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Mixte de Recherche sur le VIH et les Maladies Infectieuses Associ\u00e9es, (CIRMF-SSM), Libreville, Gabon"},{"name":"UMR IRD 224\u2014CNRS 5290\u2014MIVEGEC \u2013 Universit\u00e9 de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"2021031209280580600_dkaa537-B1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"2021031209280580600_dkaa537-B2","year":"2020"},{"key":"2021031209280580600_dkaa537-B3","year":"2014"},{"key":"2021031209280580600_dkaa537-B4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jama.2018.2093","article-title":"The global HIV epidemic: what will it take to get to the finish line?","volume":"319","author":"Katz","year":"2018","journal-title":"JAMA"},{"key":"2021031209280580600_dkaa537-B5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/cit627","article-title":"Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-Saharan Africa and southeast Asia","volume":"58","author":"Aghokeng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021031209280580600_dkaa537-B6","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/civ556","article-title":"Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis","volume":"61","author":"Boender","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021031209280580600_dkaa537-B7","year":"2017"},{"key":"2021031209280580600_dkaa537-B8","year":"2019"},{"key":"2021031209280580600_dkaa537-B9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eclinm.2019.03.013","article-title":"HIV drug resistance in resource-limited countries: threat for HIV elimination","volume":"9","author":"Ngo-Giang-Huong","year":"2019","journal-title":"EClinicalMedicine"},{"key":"2021031209280580600_dkaa537-B10","doi-asserted-by":"crossref","first-page":"17985","DOI":"10.7448\/IAS.15.2.17985","article-title":"Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon","volume":"15","author":"Liegeois","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"2021031209280580600_dkaa537-B11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/aid.2014.0035","article-title":"Challenges of antiretroviral treatment monitoring in rural and remote-access regions in Africa","volume":"30","author":"Taieb","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021031209280580600_dkaa537-B12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eclinm.2018.06.005","article-title":"Nationwide estimates of viral load suppression and acquired HIV drug resistance in Cameroon","volume":"1","author":"Tchouwa","year":"2018","journal-title":"EClinicalMedicine"},{"key":"2021031209280580600_dkaa537-B13","doi-asserted-by":"crossref","first-page":"38.","DOI":"10.1186\/s12981-015-0082-7","article-title":"Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo","volume":"12","author":"Konou","year":"2015","journal-title":"AIDS Res Ther"},{"key":"2021031209280580600_dkaa537-B14","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1093\/jac\/dky221","article-title":"Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey","volume":"73","author":"Tchouwa","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021031209280580600_dkaa537-B15","year":"2019"},{"key":"2021031209280580600_dkaa537-B16","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1093\/jac\/dkx252","article-title":"Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa","volume":"72","author":"Hunt","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021031209280580600_dkaa537-B17","doi-asserted-by":"crossref","first-page":"ofw233","DOI":"10.1093\/ofid\/ofw233","article-title":"Virologic failure and human immunodeficiency virus drug resistance in rural Cameroon with regard to the UNAIDS 90-90-90 treatment targets","volume":"3","author":"Boulle","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2021031209280580600_dkaa537-B18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/cid\/ciw001","article-title":"Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges","volume":"62","author":"Roberts","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021031209280580600_dkaa537-B19","doi-asserted-by":"crossref","first-page":"18004.","DOI":"10.7448\/IAS.16.1.18004","article-title":"Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months\u2019 antiretroviral therapy experience in Cameroon","volume":"16","author":"Aghokeng","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"2021031209280580600_dkaa537-B20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021031209280580600_dkaa537-B21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/aid.2017.0134","article-title":"Second-line antiretroviral therapy in sub-Saharan Africa: it is time to mind the gaps","volume":"33","author":"Murphy","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021031209280580600_dkaa537-B22","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa","volume":"71","author":"Boender","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021031209280580600_dkaa537-B23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1758-2652-14-30","article-title":"High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo","volume":"14","author":"Dagnra","year":"2011","journal-title":"J Int AIDS Soc"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/4\/1051\/36580547\/dkaa537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/4\/1051\/36580547\/dkaa537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T09:34:05Z","timestamp":1615541645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/4\/1051\/6046145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,23]]},"published-print":{"date-parts":[[2021,3,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa537","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,12,23]]}}}